Cost-Effectiveness of Anastrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women with Advanced Breast Cancer

Clinical Therapeutics

Volumn 25, Issue 11, 2003, Pages 2972-2987

  Simons, W Robert ^a   Jones, David ^b   Buzdar, Aman ^c  

^a Global Hlth Econ Outcomes Res I   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Anastrozole; Breast cancer; Cost effectiveness; Managed care; Tamoxifen

Indexed keywords

ANASTROZOLE; HORMONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ADVANCED CANCER; ARTICLE; BODY WEIGHT DISORDER; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG CHOICE; ECONOMIC EVALUATION; FEMALE; FIRST LINE THERAPY; GASTROINTESTINAL SYMPTOM; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HOT FLUSH; HUMAN; LETHARGY; MANAGED CARE; NAUSEA; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTPATIENT CARE; POSTMENOPAUSE; QUALITY ADJUSTED TIME TO DISEASE PROGRESSION; THROMBOEMBOLISM; TUMOR FLARE; TUMOR GROWTH; UNITED STATES; VAGINA BLEEDING; VAGINAL DRYNESS; WEIGHT GAIN;

EID: 0345095475     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80348-X     Document Type: Article

References (29)

1. Barakat RR. Benign and hyperplastic endometrial changes associated with tamoxifen use. Oncology (Huntingt). 1997;11(Suppl 1):35-37.
2. Cuzick J. Future possibilities in the prevention of breast cancer: Breast cancer prevention trials. Breast Cancer Res. 2000;2:258-263.
3. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol. 1998;45:608-612.
4. Perez Carrion R, Alberola Candel V, Calabresi F, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in post-menopausal women with advanced breast cancer. Ann Oncol. 1994;5(Suppl 7):S19-S24.
5. Falkson CI, Falkson HC. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Ann Oncol. 1996;7:465-469.
6. Thurlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HC1 (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol. 1996;7:471-479.
7. Geisler J, Detre S, Berntsen H, et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res. 2001;7:1230-1236.
8. Miller WR. Biology of aromatase inhibitors: Pharmacology/endocrinology within the breast. Endocr Relat Cancer. 1999;6:187-195.
9. Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol. 2001;79:93-102.
10. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18:3758-3767.
11. Glasziou PP, Cole BF, Gelber R, et al. Quality adjusted survival analysis with repeated quality of life measures. Stat Med. 1998;17:1215-1229.
12. Cox DR. Regression models and life tables. J Royal Stat Soc B. 1972;34:187-220.
13. Kovner E, Jonas S, eds. Health Maintenance Organization and Managed Care in Health Care Delivery in the United States. New York: Springer Publishing Co; 1999.
14. First DataBank. Price alert: The official guide to AWP pricing. The Knowledge Inside. San Bruno, Calif: First DataBank; 2002.
15. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000;18:3748-3757.
16. Ellsworth AJ, Witt DM, Dugdale DC, Oliver LM. Mosby's 2001-2002 Medical Drug Reference. St. Louis, Mo: Mosby, Inc; 2001.
17. Maddala GS. Limited-Dependent and Qualitative Variables in Econometrics. New York: Cambridge University Press; 1983.
18. Tobin J. Estimation of relationships for limited dependent variables. Econometrica. 1958;28:24-36.
19. Baker MS, Kessler LG, Urban N, Smucker RC. Estimating the treatment costs of breast and lung cancer. Med Care. 1991;29:40-49.
20. Simon MS, Ibrahim D, Newman L, Stano M. Efficacy and economics of hormonal therapies for advanced breast cancer. Drugs Aging. 2002;19:453-463.
21. Barnett A, Birnbaum H, Cremieux PY, et al. The costs of cancer to a major employer in the United States: A case-control analysis. Am J Manag Care. 2000;6:1243-1251.
22. Drummond M, Thompson E, Howell A, et al. Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer. J Med Econ. 1999;2:33-43.
23. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369-390.
24. Milla-Santos A, Milla L, Portella J, et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, Phase III study. Am J Clin Oncol. 2003;26:317-322.
25. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-1467.
26. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol. 1995;13:513-529.
27. Brodie AM, Njar VC. Aromatase inhibitors in advanced breast cancer: Mechanism of action and clinical implications. J Steroid Biochem Mol Biol. 1998;66:1-10.
28. Simons WR, Grace EM. Cost-effectiveness of anastrozole compared to tamoxifen in the treatment of post-menopausal women with breast cancer. Presented at: Second European Conference on the Economics of Cancer; September 3-5, 2000; Brussels, Belgium. Eur J Cancer. 2000;36(Suppl 3):S7. Abstract OP26.
29. Simons WR, Bassi R, Jones D, Barrett Lee P. Cost-effectiveness analysis of anastrozole versus tamoxifen as 1st-line therapy in postmenopausal women with HR+ advanced breast cancer: A UK perspective. Presented at European Breast Cancer Conference; March 19-23, 2002; Barcelona, Spain. Eur J Cancer. 2002;38(Suppl 3):S68. Abstract 116.